BREAST-CANCER .3.

被引：205

作者：

HARRIS, JR

LIPPMAN, ME

VERONESI, U

WILLETT, W

机构：

[1] BETH ISRAEL HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02215

[2] HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT RADIAT ONCOL,BOSTON,MA 02115

[3] GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007

[4] IST NAZL STUDIO & CURA TUMORI,I-20133 MILAN,ITALY

[5] GEORGETOWN UNIV,MED CTR,DEPT MED,WASHINGTON,DC 20007

[6] GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007

[7] HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115

[8] HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115

[9] HARVARD UNIV,SCH MED,CHANNING LAB,DEPT MED,BOSTON,MA 02115

[10] BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1992年 / 327卷 / 07期

关键词：

D O I：

10.1056/NEJM199208133270706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Adjuvant Therapy of Breast Cancer The demonstration that adjuvant systemic therapy (i.e., systemic therapy given at the time of primary local treatment in the absence of demonstrated metastases) can prolong the disease-free interval and improve overall survival has been a major advance in the management of breast cancer. Randomized clinical trials of systemic adjuvant therapy were pioneered by the Istituto Nazionale per lo Studio e la Cura dei Tumori176 and the National Surgical Adjuvant Breast and Bowel Project177 and provided the first evidence of the benefit of cytotoxic chemotherapy in women with involvement of axillary lymph nodes, particularly younger women… © 1992, Massachusetts Medical Society. All rights reserved.

引用

页码：473 / 480

页数：8

共 86 条

[1] COMPARATIVE-STUDY OF HARVEY-RAS ONCOGENE EXPRESSION WITH CONVENTIONAL CLINICOPATHOLOGICAL PARAMETERS OF BREAST-CANCER [J].